SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy

An SI Board Since February 1997

Posts	SubjectMarks	Bans	Symbol
184	8	0	SANG

Emcee: Carson O. Ray, Jr.	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
109	Todd, I have been out of town quite a bit recently, but I do have the followin	deadstrait	-	4/6/1998
108	Deadstraight, Talked to a friend that is a MM at the Chicago Stock exchange an	Todd A. Sinelli	-	3/19/1998
107	Todd, I wish it were me doing all that buying. What I think we are seeing is	deadstrait	-	3/18/1998
106	wow, watching the tape today there were some HUGE trades; yet the market in SAN	Todd A. Sinelli	-	3/16/1998
105	I think it must be the gambler which is inside all of us. If we each didn'	deadstrait	-	3/6/1998
104	any comments in regards to the increased short interest? curious who's bet	Todd A. Sinelli	-	3/6/1998
103	On Feb 12, Sangstat announced that they were responding to the FDA regarding t	deadstrait	-	3/5/1998
102	short interest, hmmm. short interest just hit record levels: viwes.com with	Todd A. Sinelli	-	3/5/1998
101	Any comments, discussion out there? SANG seems to be languishing in the $30	Todd A. Sinelli	-	2/27/1998
100	FYI: Brokerage Firm Date of Last Re	Todd A. Sinelli	-	2/23/1998
99	hmmm, if you're using a p/e of 40 with eps est. of $2.47 for 99 that would	Todd A. Sinelli	-	2/23/1998
98	I hope this will answer your questions. The following info was updated as of J	deadstrait	-	2/23/1998
97	The $60 price target is based on 1999 earnings estimate, with a PE of 40. The	deadstrait	-	2/23/1998
96	Could someone back through how H & Q gets a target price of $60? this is a	Todd A. Sinelli	-	2/22/1998
95	More importantly--you'll not find a dishonest one.	deadstrait	-	2/22/1998
94	So where is an honest profile?	John S. Sturges	-	2/21/1998
93	On Feb 13, 1998, H&Q reiterated their strong buy rating on SANG with a 12	deadstrait	-	2/21/1998
92	The Product License Application (PLA) for Thymo has been reviewed by the FDA. S	deadstrait	-	2/21/1998
91	No personal vendetta here. If you will reread my post, you will find that wha	deadstrait	-	2/21/1998
90	The fact still remains 2 top transplant centers chose Zenapax and dropped Cyclo	John S. Sturges	-	2/20/1998
89	Well, it is past the 18th and it looks to me as if PDLI didn't do all that	deadstrait	-	2/20/1998
88	Zenapax Combination Therapy vs. Cyclosporin News of cylcosporin's demise	TheDrugMan	-	2/18/1998
87	I am not interested in discussing merits and vested interests that some investm	Darth Vader	-	2/18/1998
86	Cyclosporin vs Zenapax-top transplant centers choose Zenapax. University of Cal	John S. Sturges	-	2/17/1998
85	I couldn't agree more	deadstrait	-	2/17/1998

Go to reply# or date (mm/dd/yy):